Polymyalgia Rheumatica Research Studies

The Division of Rheumatology strives to understand and help provide better treatments for Polymyalgia Rheumatica (PMR) through research. Please see the list below which provides a summary of the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease. 

Study Name/IRB#/PIBrief Description​Basic Eligibility​ CriteriaContact​



IRB# 23-1918

PI:  Elena Weinstein, MD


The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed.

To see clinical trials.gov info click here


  • Male or non-pregnant, non-lactating female.
  • Age 50 or older
  • History of being treated with at least 8 consecutive weeks with prednisone (≥ 10 mg/day or equivalent) at any time prior to screening

Chong Pedrick



Najeeb Arishi




Rheumatology (SOM)

CU Anschutz

Barbara Davis Center for Diabetes

1775 North Aurora Court


Aurora, CO 80045


CMS Login